Fewer people than before are being diagnosed with and dying from cancer in Appalachia, but cancer incidence and death rates remain substantially higher, especially in certain areas of Central Appalachia, compared to elsewhere in the U.S.
Telisotuzumab vedotin shows promising results in asian patients with c-Met overexpressing NSCLC
The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor
September 11, 2024